Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$148.5M, compared with -$195.33M a year earlier.
Context
- Net debt amounted to 19.9% of total assets at the end of Q1 FY2026, down 38.7 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +24.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (30.68M) USD
- Year-over-year change
- +90.4%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (30.68M) | +90.4% |
| FY2024 | 2024-12-31 | (318.74M) | -791.7% |
| FY2023 | 2023-12-31 | (35.74M) | +45.6% |
| FY2022 | 2022-12-31 | (65.68M) | — |
Net Debt vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's Mar 2026 net debt of -$148.5M is the 5th highest of the 8 companies compared; the peer median is -$95.61M.
- Its year-over-year change of +24.0% is the highest of 7, against a peer median of -17.8%.
- Net debt amounts to 19.9% of total assets for ZBIO, versus a peer median of 57.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | -$3.55M | +1.8% | — | 30.9% | |
| Mar 2026 | -$26.68M | +4.3% | — | 13.4% | |
| Mar 2026 | -$39.76M | +14.8% | — | 62.4% | |
UPBUpstream Bio, Inc. | Mar 2026 | -$95.61M | -37.3% | — | 30.1% |
| Mar 2026 | -$148.5M | +24.0% | — | 19.9% | |
| Mar 2026 | -$149.77M | -117.7% | — | 57.0% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | -$248.47M | — | — | 85.5% |
| Sep 2026 | -$722.27M | -38.4% | — | 94.9% | |
| Peer median (excluding ZBIO) | -$95.61M | -17.8% | — | 57.0% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.